Market research
CIR.LSE Circassia Group Plc
LSE GBP Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 143M
- P/E ratio
- 34.0
- Analyst target
- 47
- Dividend yield
- 0.0%
- Beta
- 1.56
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB00BJVD3B28
- Market cap
- 143M
- P/E ratio
- 34.0
- Analyst target
- 47
- Dividend yield
- 0.0%
- Beta
- 1.56
About
About Circassia Group Plc
Circassia Group Plc, a medical device company, focuses on the respiratory diagnostics and monitoring products in the United States, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It offers NIOX and NIOX VERO, a fractional exhaled nitric oxide measurement and monitoring products for use in asthma diagnosis and management. The company offers its products approximately in 50 countries through a network of distribution partners. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Research context
Circassia Group Plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CIR.LSE discussion.
5 years, 6 months ago
Circassia Group Plc is currently in a long term downtrend where the price is trading 53.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Finally, its free cash flow grew by 34.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Circassia Group Plc gets an overall score of 2/5.